Multiple System Atrophy Pipeline Insight

DelveInsight’s, “Multiple System Atrophy Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Multiple System Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Multiple System Atrophy Understanding

Multiple System Atrophy Overview

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects multiple parts of the nervous system, particularly those responsible for movement and autonomic functions such as blood pressure regulation, bladder control, and balance. MSA is characterized by the abnormal accumulation of alpha-synuclein protein in glial cells, leading to widespread nerve cell dysfunction and degeneration.

Clinically, MSA is divided into two primary types: MSA-P, which is dominated by parkinsonian features including bradykinesia, rigidity, tremor, and postural instability, and MSA-C, which is characterized mainly by cerebellar symptoms such as poor coordination, gait instability, speech difficulties, and abnormal eye movements. The exact cause of MSA remains unknown, with most cases occurring sporadically without a clear hereditary pattern, although the accumulation of misfolded alpha-synuclein is central to the disease’s pathophysiology.

Diagnosis is primarily clinical, relying on careful evaluation of movement and autonomic symptoms, neurological examination, imaging techniques such as MRI to rule out other conditions, and assessment of response to Parkinson’s medications, which is often minimal or transient. Definitive confirmation, however, is only possible postmortem.

Currently, there is no cure or disease-modifying treatment for MSA. Management focuses on symptomatic relief and supportive care, including medications to regulate blood pressure and bladder function, physical and occupational therapy to maintain mobility and daily functioning, speech therapy, nutritional support, and palliative care as the disease progresses. Research continues into potential therapies targeting the underlying protein accumulation, but these remain largely in preclinical or early clinical stages.

 

"Multiple System Atrophy Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple System Atrophy pipeline landscape is provided which includes the disease overview and Multiple System Atrophy treatment guidelines. The assessment part of the report embraces, in depth Multiple System Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple System Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Recognize early signs of Multiple System Atrophy and seek expert care today to manage symptoms and improve quality of life.

Multiple System Atrophy Pipeline Report Highlights

• The Multiple System Atrophy companies and academics are working to assess challenges and seek opportunities that could influence Multiple System Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Multiple System Atrophy.

Multiple System Atrophy Emerging Drugs Chapters

This segment of the Multiple System Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Multiple System Atrophy Emerging Drugs

• Amlenetug: H. Lundbeck A/S

Amlenetug (also known as Lu AF82422), developed by H. Lundbeck A/S, is an investigational human monoclonal antibody designed to target neurodegenerative processes in multiple system atrophy. The drug specifically binds to extracellular α-synuclein, a pathological protein implicated in MSA, with the aim of preventing its uptake into cells and inhibiting the seeding and spread of toxic protein aggregates across the brain, additionally, through its active Fc region, it may enhance immune-mediated clearance of α-synuclein via microglial activity, thereby potentially slowing disease progression. The drug has received several important designations, including FDA Fast Track designation (2025), Orphan Drug Designation in the US, EU, and Japan, and SAKIGAKE designation in Japan, highlighting its potential to address a significant unmet medical need. Currently, amlenetug is in Phase III clinical development, being evaluated in the global MASCOT trial (NCT06706622), a randomized, double-blind, placebo-controlled study assessing its efficacy, safety, and tolerability in patients with MSA, with dosing administered via intravenous infusion approximately every four weeks.

• ATH434: Alterity Therapeutics

ATH434, developed by Alterity Therapeutics, is an investigational oral small-molecule therapeutic designed to treat neurodegenerative diseases such as multiple system atrophy (MSA). The drug acts as an iron chaperone, targeting pathological processes by redistributing excess iron in the brain and inhibiting α-synuclein aggregation, which is a key driver of neurodegeneration in MSA, ATH434 aims to protect neurons and slow disease progression. ATH434 is being developed primarily for MSA, a rare and rapidly progressive neurodegenerative disorder with significant unmet medical need. The drug has received Orphan Drug Designation from the U.S. FDA and the European Commission, as well as FDA Fast Track designation, underscoring its potential clinical importance. Clinically, ATH434 has completed Phase II trials (ATH434-201/202), and based on positive data, the program is advancing toward Phase III development, positioning it as a late-stage asset in Alterity’s pipeline.

• hOMSC300: Cytora Ltd.

hOMSC300, developed by Cytora Ltd., is an investigational allogeneic, off-the-shelf cell therapy, a unique stem cell population derived from the neural crest with properties of neural, mesenchymal, and regenerative cells. These cells exhibit a dual mechanism of action involving cell replacement and paracrine trophic effects, enabling neuroprotection, regeneration, and modulation of neuroinflammation, which are key pathological processes in neurodegenerative diseases. The therapy is being developed for multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder affecting autonomic and motor functions, and aims to act as a disease-modifying treatment by slowing disease progression and preserving neuronal function. From a clinical development perspective, Cytora’s pipeline clearly indicates that hOMSC300 is currently in Phase I clinical studies for MSA, with ongoing trials evaluating safety and preliminary efficacy following intrathecal administration.

• AB-1005: AskBio

AB-1005 is an investigational gene therapy developed by AskBio, a wholly owned subsidiary of Bayer AG. The therapy is based on an adeno-associated viral vector serotype 2 (AAV2) designed to deliver the gene encoding glial cell line-derived neurotrophic factor (GDNF) directly into the brain. Mechanistically, AB-1005 enables sustained local production of GDNF within targeted brain regions, which is intended to support the survival and function of dopaminergic neurons and enhance dopamine signaling, thereby addressing the underlying neurodegeneration. The therapy is currently being investigated in the Phase I stage of its development for the treatment of Multiple System Atrophy – parkinsonian type (MSA-P).

Further product details are provided in the report……..

Multiple System Atrophy Therapeutic Assessment

This segment of the report provides insights about the different Multiple System Atrophy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Multiple System Atrophy

There are approx. 20+ key companies which are developing the therapies Multiple System Atrophy. The companies which have their Multiple System Atrophy drug candidates in the most advanced stage, i.e. Phase III include, H. Lundbeck A/S, and others.

Multiple System Atrophy Clinical Trial Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Multiple System Atrophy Route of Administration

Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Multiple System Atrophy Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Multiple System Atrophy Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Multiple System Atrophy Clinical Trial Activities

The Multiple System Atrophy Pipeline report provides insights into different Multiple System Atrophy clinical trials within phase II, I, preclinical and discovery stage. It also analyses Multiple System Atrophy therapeutic drugs, key players involved in developing key drugs.

Multiple System Atrophy Pipeline Development Activities

The Multiple System Atrophy clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple System Atrophy drugs.

Multiple System Atrophy Pipeline Report Insights

• Multiple System Atrophy Pipeline Analysis
• Multiple System Atrophy Therapeutic Assessment
• Multiple System Atrophy Unmet Needs
• Impact of Multiple System Atrophy Drugs

Multiple System Atrophy Pipeline Report Assessment

• Multiple System Atrophy Pipeline Product Profiles
• Multiple System Atrophy Therapeutic Assessment
• Multiple System Atrophy Pipeline Assessment
• Multiple System Atrophy Inactive drugs assessment
• Multiple System Atrophy Market Unmet Needs

Support research and awareness about Multiple System Atrophy to accelerate diagnosis, advance treatments, and bring hope to patients and families.

Key Questions Answered In The Multiple System Atrophy Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Multiple System Atrophy drugs?
• How many Multiple System Atrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple System Atrophy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple System Atrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Multiple System Atrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Multiple System Atrophy Key Players

• Cytora Ltd.
• Alterity Therapeutics
• H. Lundbeck A/S
• AskBio
• Corestemchemon, Inc.
• Tiziana Life Sciences LTD
• Kainos Medicine Inc.
• Ono Pharmaceutical Co. Ltd
• Teva Pharmaceutical Industries Ltd.
• ProMIS Neurosciences, Inc.
• Ionis Pharmaceuticals, Inc.
• Yoda Therapeutics Inc

Multiple System Atrophy Key Products

• Amlenetug
• ATH434
• hOMSC300
• AB-1005
• CS10BR05
• Foralumab
• KM-819
• ONO-2808
• TEV-56286
• PMN442
• ION464
• YA-101